Ying Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock

Key Points

• CEO Ying Luo sold 10,136 shares at an average price of $8.04 (totaling $81,493), reducing her stake by 0.39% to 2,565,226 shares valued at about $20.62 million.
• Gyre missed quarterly expectations, reporting EPS of -$0.10 vs. -$0.06 expected and revenue of $22.52 million versus a $31.61 million estimate.
• The stock fell to $7.07 (down $0.97) on above-average volume (167,488 vs. 55,514 average), carries a market cap of ~$685.7 million, and has mixed analyst coverage with an average rating of "Hold" and a $17 price target.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) CEO Ying Luo sold 10,136 shares of the firm's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the transaction, the chief executive officer owned 2,565,226 shares of the company's stock, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gyre Therapeutics Price Performance

Gyre Therapeutics stock traded down $0.97 during mid-day trading on Thursday, reaching $7.07. The stock had a trading volume of 167,488 shares, compared to its average volume of 55,514. Gyre Therapeutics, Inc. has a one year low of $6.57 and a one year high of $11.78. The company has a 50-day moving average price of $7.58 and a two-hundred day moving average price of $7.69. The company has a market capitalization of $685.72 million, a price-to-earnings ratio of 707.71 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04). The firm had revenue of $22.52 million for the quarter, compared to the consensus estimate of $31.61 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. On average, equities research analysts anticipate that Gyre Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on GYRE shares. Wall Street Zen lowered shares of Gyre Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, March 14th. Weiss Ratings reissued a "sell (d)" rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research cut Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $17.00.

Institutional Investors Weigh In On Gyre Therapeutics

A number of large investors have recently added to or reduced their stakes in GYRE. Dimensional Fund Advisors LP lifted its holdings in shares of Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after buying an additional 14,365 shares during the period. Bank of New York Mellon Corp increased its position in Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock valued at $301,000 after acquiring an additional 1,941 shares during the last quarter. Barclays PLC increased its position in Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company's stock valued at $131,000 after acquiring an additional 5,135 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock valued at $1,194,000 after acquiring an additional 45,772 shares during the period. Finally, State Street Corp lifted its holdings in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company's stock valued at $1,428,000 after acquiring an additional 19,472 shares during the period. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.